Journal
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
Volume 12, Issue 10, Pages 1047-1057Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/1744666X.2016.1189826
Keywords
JAK inhibitors; RA; dendritic cell; T cell; B cell
Categories
Funding
- Ministry of Health, Labor and Welfare of Japan
- Ministry of Education, Culture, Sports, Science and Technology of Japan
- University of Occupational and Environmental Health, Japan
- UOEH
- Mitsubishi-Tanabe
- Eisai
- Chugai
- Abbott Japan
- Astellas
- Daiichi-Sankyo
- Abbvie
- Janssen
- Pfizer
- Takeda
- Astra-Zeneca
- Eli Lilly Japan
- GlaxoSmithKline
- Quintiles
- MSD
- Asahi-Kasei
- Bristol-Myers
Ask authors/readers for more resources
Introduction: Treatment of rheumatoid arthritis (RA) has improved considerably following the advent of biologic disease-modifying anti-rheumatic drugs (DMARDs). However, these drugs require special storage and transportation. Janus kinase (JAK) inhibitors are oral synthetic DMARDs that inhibit the non-receptor tyrosine kinase family Janus kinase. Recently, many JAK inhibitors are being developed as new therapies for patients with RA.Areas covered: In this article, we mainly review the efficacy and safety of JAK inhibitors currently under investigation. Tofacitinib has already been approved in 43 countries except in the EU. Results of three JAK inhibitors (baricitinib, decernotinib, and peficitinib) in phase III are consistent with that of tofacitinib. Tofacitinib and baricitinib were partially effective in patients who had an inadequate response to biological DMARDs.Expert commentary: JAK kinase inhibitors provide a new therapeutic approach for rheumatoid arthritis. Meanwhile, further studies are needed to determine their risk-benefit ratio and the most appropriate patients suitable for such therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available